Improving Access to Abortion in Georgia

  Center for Information and Counseling on Reproductive Health – Tanadgoma

In Georgia, 3 visits to a health facility are required to have an abortion: an initial consultation; a second visit after a minimum five-day waiting period for the abortion procedure or prescription of medical abortion pills; and a follow-up visit to confirm the abortion was successful. This creates unnecessary barriers for women seeking abortion, especially those living in rural areas. The team will address this challenge by implementing and testing a simplified one-visit service delivery model. Through this model, women only require one visit to a health facility for pregnancy diagnosis and counselling. Five days later, the health provider will distantly get confirmation from the patient, then mail medical abortion pills and two multi-level urine pregnancy tests to the patient, so that the medical abortion can be self-administered, and the success can be confirmed without an in-person assessment.



Mifepristone 50 mg as a Contraceptive

  Women on Web                 Georgia

Key to addressing unmet contraceptive need in the developing world is the development of on-demand contraceptives without the side-effects and health risks associated with hormonal methods. Mifepristone 50 mg, a once-a-week non-hormonal contraceptive that is also effective as a morning-after pill and to induce early abortion, is an exciting new option for fertility regulation. This project is a phase III multicenter double-blind randomized non-inferiority trial in Georgia comparing the contraceptive use of weekly mifepristone 50 mg with daily desogestrel 0.075 mg. Trial objectives are to establish the efficacy, safety and side-effects of mifepristone 50 mg as a weekly contraceptive. The long-term goal of the project is to register and market mifepristone 50 mg as a contraceptive and to have this indication included on the World Health Organization Essential Medicines List.